IPPRA / Grant Monitor

2026-07-07
← Board

DoW Breast Cancer, Transformative Breast Cancer Consortium Award

HT942526BCRPTBCCA · Defense Health Agency Contracting Activity - DHACA

biomedical clinical public health mental behavioral health social services Science & Technology R&D

Closes
2026-09-30 · 85 d
Award ceiling
Award floor
Program funding
$35,000,000
Expected awards
1
Cost sharing
No
Posted
2026-05-04
Instrument
Cooperative Agreement
Characterization · gpt-5.4-mini · 2026-07-07

Funds a highly integrated, multidisciplinary, multi-institutional breast cancer consortium with leading scientists, clinicians, and consumer advocates to address major breast cancer problems with transformative impact.

Funds
applied research
University
direct
social behavioral
substantial
physical sciences
minor
engineering
minor
life biomedical
central
computational data
substantial

⚑ Multi-institutional consortium required · Up to five PIs total (Consortium Director + 3-4 Project Team PIs) · At least one breast cancer consumer advocate required per project team · Only Consortium Director submits pre-application; all PIs must submit full application components by deadline or application may be withdrawn

Unit fits — one characterization, each unit's own rules

Physical Sciences & Engineering (demo) 70 strong technical depth: substantial; funds applied research
IPPRA 58 good peripheral portfolio topic: public_health; signature methods: community engaged; social/behavioral work is substantial; funds applied research; biomedical core — IPPRA health lane is communication/crisis/policy (capped); clinical-trial/biomedical core — IPPRA angle is policy/community (capped)
Tom Love Innovation Hub 30 weak funds applied research; deep-tech content

Description

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Award supports collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. Applications must propose a synergistic, highly integrated, multidisciplinary and multi-institutional consortium of leading scientists, clinicians and breast cancer consumer advocates that will address a major problem in a way that a single investigator or group could not accomplish. The consortium’s collaborative efforts must make a transformative impact in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. If the application addresses a different fundamental issue, the application must couple it with at least one of the overarching challenges.

Distinctive Features: This funding mechanism allows for up to five Principal Investigators (PIs) which includes the Consortium Director and three or four Project Team PIs. Applications must include at least one breast cancer consumer advocate per project team. Only the Consortium Director will submit a pre-application, but all PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Consortium Director and Project Team PIs) applications by the full application deadline may result in administrative withdrawal.

Apply

View on Grants.gov → CONTACT: Jamie Shortall Grant Officer <help@eBRAP.org>

Proposal brief SEE AN EXAMPLE →

A one-page internal memo: fit assessment, submission requirements, document scaffold, and next steps dated back from the deadline — tailored to your project idea if you add one.

ONE LLM CALL (~1¢) · CACHED · REQUIRES STAFF KEY

Proposal shell · Department of Defense (BAA-style) conventions SEE A DOD EXAMPLE →

Funder-faithful document skeletons — Department of Defense (BAA-style)'s document set with section headings, page limits, reviewer guidance, and writing prompts; add a project idea to get [DRAFT] starter bullets. Download as .md for Word or Overleaf.

ONE LLM CALL (~2-3¢) · CACHED · SCAFFOLDING, NOT GHOSTWRITING